COVID-19 Prevention Guidance and the Incidence of Febrile Neutropenia in Patients with Breast Cancer Receiving TAC Chemotherapy with Prophylactic Pegfilgrastim
Chemotherapy-induced febrile neutropenia (FN) is a medical emergency that causes severe adverse effects and death. Respiratory infections are one of the main causes of fever in patients with FN. We studied whether infection prevention and control (IPC) guidance for coronavirus 2019 disease reduced t...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-11-01
|
| Series: | Journal of Clinical Medicine |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2077-0383/11/23/7053 |
| _version_ | 1797462961081548800 |
|---|---|
| author | Hongki Gwak Seung-Taek Lim Ye-Won Jeon Hyung Soon Park Seong Hwan Kim Young-Jin Suh |
| author_facet | Hongki Gwak Seung-Taek Lim Ye-Won Jeon Hyung Soon Park Seong Hwan Kim Young-Jin Suh |
| author_sort | Hongki Gwak |
| collection | DOAJ |
| description | Chemotherapy-induced febrile neutropenia (FN) is a medical emergency that causes severe adverse effects and death. Respiratory infections are one of the main causes of fever in patients with FN. We studied whether infection prevention and control (IPC) guidance for coronavirus 2019 disease reduced the incidence of FN. We reviewed female patients with breast cancer treated with adjuvant docetaxel, doxorubicin, and cyclophosphamide with prophylactic pegfilgrastim between 2019 and 2021. IPC guidance was implemented in April 2020. There was no difference in the incidence of chemotherapy-induced neutropenia between patients with and without IPC. In patients with IPC, the incidence of FN (9.5%) was lower than that of patients without IPC (27.9%). The hospitalization duration (0.7 ± 1.5 days) and total hospital cost (279.6 ± 42.6 USD) of the IPC group were significantly lower than that of the non-IPC group (2.0 ± 3.8 days and 364.7 ± 271.6 USD, respectively). IPC guidance should be implemented to prevent FN in high-risk patients with breast cancer. |
| first_indexed | 2024-03-09T17:43:57Z |
| format | Article |
| id | doaj.art-c7e821e8f3c94d7784745ec86119775e |
| institution | Directory Open Access Journal |
| issn | 2077-0383 |
| language | English |
| last_indexed | 2024-03-09T17:43:57Z |
| publishDate | 2022-11-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Journal of Clinical Medicine |
| spelling | doaj.art-c7e821e8f3c94d7784745ec86119775e2023-11-24T11:22:08ZengMDPI AGJournal of Clinical Medicine2077-03832022-11-011123705310.3390/jcm11237053COVID-19 Prevention Guidance and the Incidence of Febrile Neutropenia in Patients with Breast Cancer Receiving TAC Chemotherapy with Prophylactic PegfilgrastimHongki Gwak0Seung-Taek Lim1Ye-Won Jeon2Hyung Soon Park3Seong Hwan Kim4Young-Jin Suh5Division of Breast and Thyroid Surgical Oncology, Department of Surgery, Hwahong Hospital, Suwon 16630, Republic of KoreaDivision of Breast and Thyroid Surgical Oncology, Department of Surgery, St. Vincent’s Hospital, College of Medicine, The Catholic University of Korea, Seoul 16247, Republic of KoreaDivision of Breast and Thyroid Surgical Oncology, Department of Surgery, St. Vincent’s Hospital, College of Medicine, The Catholic University of Korea, Seoul 16247, Republic of KoreaDivision of Medical Oncology, Department of Internal Medicine, St. Vincent’s Hospital, College of Medicine, The Catholic University of Korea, Seoul 16247, Republic of KoreaDepartment of Plastic and Reconstructive Surgery, Kangnam Sacred Heart Hospital, Hallym University College of Medicine, Seoul 07441, Republic of KoreaDivision of Breast and Thyroid Surgical Oncology, Department of Surgery, St. Vincent’s Hospital, College of Medicine, The Catholic University of Korea, Seoul 16247, Republic of KoreaChemotherapy-induced febrile neutropenia (FN) is a medical emergency that causes severe adverse effects and death. Respiratory infections are one of the main causes of fever in patients with FN. We studied whether infection prevention and control (IPC) guidance for coronavirus 2019 disease reduced the incidence of FN. We reviewed female patients with breast cancer treated with adjuvant docetaxel, doxorubicin, and cyclophosphamide with prophylactic pegfilgrastim between 2019 and 2021. IPC guidance was implemented in April 2020. There was no difference in the incidence of chemotherapy-induced neutropenia between patients with and without IPC. In patients with IPC, the incidence of FN (9.5%) was lower than that of patients without IPC (27.9%). The hospitalization duration (0.7 ± 1.5 days) and total hospital cost (279.6 ± 42.6 USD) of the IPC group were significantly lower than that of the non-IPC group (2.0 ± 3.8 days and 364.7 ± 271.6 USD, respectively). IPC guidance should be implemented to prevent FN in high-risk patients with breast cancer.https://www.mdpi.com/2077-0383/11/23/7053COVID-19infection preventionfebrile neutropeniabreast cancer |
| spellingShingle | Hongki Gwak Seung-Taek Lim Ye-Won Jeon Hyung Soon Park Seong Hwan Kim Young-Jin Suh COVID-19 Prevention Guidance and the Incidence of Febrile Neutropenia in Patients with Breast Cancer Receiving TAC Chemotherapy with Prophylactic Pegfilgrastim Journal of Clinical Medicine COVID-19 infection prevention febrile neutropenia breast cancer |
| title | COVID-19 Prevention Guidance and the Incidence of Febrile Neutropenia in Patients with Breast Cancer Receiving TAC Chemotherapy with Prophylactic Pegfilgrastim |
| title_full | COVID-19 Prevention Guidance and the Incidence of Febrile Neutropenia in Patients with Breast Cancer Receiving TAC Chemotherapy with Prophylactic Pegfilgrastim |
| title_fullStr | COVID-19 Prevention Guidance and the Incidence of Febrile Neutropenia in Patients with Breast Cancer Receiving TAC Chemotherapy with Prophylactic Pegfilgrastim |
| title_full_unstemmed | COVID-19 Prevention Guidance and the Incidence of Febrile Neutropenia in Patients with Breast Cancer Receiving TAC Chemotherapy with Prophylactic Pegfilgrastim |
| title_short | COVID-19 Prevention Guidance and the Incidence of Febrile Neutropenia in Patients with Breast Cancer Receiving TAC Chemotherapy with Prophylactic Pegfilgrastim |
| title_sort | covid 19 prevention guidance and the incidence of febrile neutropenia in patients with breast cancer receiving tac chemotherapy with prophylactic pegfilgrastim |
| topic | COVID-19 infection prevention febrile neutropenia breast cancer |
| url | https://www.mdpi.com/2077-0383/11/23/7053 |
| work_keys_str_mv | AT hongkigwak covid19preventionguidanceandtheincidenceoffebrileneutropeniainpatientswithbreastcancerreceivingtacchemotherapywithprophylacticpegfilgrastim AT seungtaeklim covid19preventionguidanceandtheincidenceoffebrileneutropeniainpatientswithbreastcancerreceivingtacchemotherapywithprophylacticpegfilgrastim AT yewonjeon covid19preventionguidanceandtheincidenceoffebrileneutropeniainpatientswithbreastcancerreceivingtacchemotherapywithprophylacticpegfilgrastim AT hyungsoonpark covid19preventionguidanceandtheincidenceoffebrileneutropeniainpatientswithbreastcancerreceivingtacchemotherapywithprophylacticpegfilgrastim AT seonghwankim covid19preventionguidanceandtheincidenceoffebrileneutropeniainpatientswithbreastcancerreceivingtacchemotherapywithprophylacticpegfilgrastim AT youngjinsuh covid19preventionguidanceandtheincidenceoffebrileneutropeniainpatientswithbreastcancerreceivingtacchemotherapywithprophylacticpegfilgrastim |